Navigation Links
Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes
Date:9/10/2009

MINNEAPOLIS, Sept. 10 /PRNewswire/ -- Exsulin Corporation today announced the start of a phase II human clinical trial of Exsulin(TM), a peptide drug product aimed at restoring insulin production in people with diabetes mellitus. The randomized, controlled 12-week trial in patients with established Type 1 diabetes (T1DM) will be co-led by Mayo Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, Canada. First results are expected to be available in Q2 2010. The design of the study is based on previous trials which showed improvement in insulin secretion and glucose control in both Type 1 and Type 2 diabetes (T2DM) patients treated with Exsulin.

Diabetes is a life-threatening condition affecting nearly 24 million people in the United States, and more than 200 million worldwide. It remains one of medicine's most significant and costly chronic diseases, and its prevalence is expected to grow due to the global obesity epidemic and the aging of the population. T1DM develops when the body's immune system destroys pancreatic beta cells that make insulin, the key hormone responsible for controlling blood sugar levels. All people with T1DM require insulin therapy to survive. People with T2DM have insufficient insulin secretion and uptake, and often require insulin therapy as their disease progresses. Poorly controlled diabetes can lead to serious complications, including blindness, kidney failure and death.

"Exsulin is a hormone that is being studied for its potential ability to regenerate islets - and possibly restore insulin production -- in the pancreas," said G. Alexander Fleming, MD, founder and chairman, Exsulin Corporation. "We look forward to the results of this important study, which will build on previous findings and further characterize the effects of Exsulin on insulin production and glucose control."

"This phase II tri
'/>"/>

SOURCE Exsulin Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, announced ... from Hercules Technology Growth Capital, Inc. (NYSE: ... final advance under the Loan and Security Agreement that ... , Alimera Sciences Limited, entered into with Hercules in ...
(Date:9/30/2014)... 30, 2014 A study using a relatively ... new look at the composition of carotid artery disease ... and treat the disease, a leading cause of stroke. ... Lexington between September 2010 and May 2012, was featured ... of the American College of Cardiology (JACC) Cardiovascular Interventions. ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
(Date:9/30/2014)... has been awarded a three-year $1.7 million grant ... develop new imaging technologies and data analysis techniques ... networks of neurons in the brain interact to ... identify the precise interactions between millions of nerve ... and alterations in these interactions that may be ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... option to help diabetics curb their sweet tooth, but ... Nature this September, suggests that zero-calorie sweeteners may ... 2 diabetes. , The Weizmann Institute of Science ... fed artificial sweeteners to mice, the mice developed glucose ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set to open ... RMS welcomes the launch of an entirely new facility, ... new treatment center for the Lung Institute. , ... Nashville, the hope is to bring awareness to those ... undiagnosed. With Nashville being a hub for medical technology, ...
(Date:9/30/2014)... Sept. 30, 2014 (HealthDay News) -- Medicare should cover ... high risk for the disease, a coalition of more ... coalition, which includes the Lung Cancer Alliance, the Society ... American Cancer Society and the American Society of Clinical ... to the U.S. Centers for Medicare & Medicaid Services ...
(Date:9/30/2014)... Chicago, IL (PRWEB) September 30, 2014 ... meet at the National Association of Health Advocacy Consultants ... of Healthcare Advocacyā€¯ (#NAHAC14) to be held October 30th ... Making its debut at NAHAC14: Standards and Best Practices ... advocacy grows into a profession, advocates have needed a ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... 2012 - VIB researcher Diether Lambrechts, associated with KU ... which patients will benefit more from treatment with bevacizumab ... step towards personalized medicine and patient-tailored use of this ... Leuven) said "in two large clinical studies with patients ...
... symptoms of heart disease already have heart damage, according to ... Heart Failure Congress 2012 , 19-22 May, in Belgrade, Serbia. ... Failure Association of the European Society of Cardiology., ... research has shown that obese adults have structural and functional ...
... Reinberg HealthDay Reporter , FRIDAY, May 18 (HealthDay News) ... Americans born between 1945 and 1965 -- the baby boom generation ... deadly disease occur in this age group, and most were infected ... the agency said. "CDC views this as an unrecognized health ...
... combination of three drugs used worldwide as the standard of ... of death or hospitalization, and should not be used together ... the surprising results of a rigorous independent study. The ... New England Journal of Medicine to coincide with a ...
... For more than three decades, researchers have warned of ... tobacco smoke (ETS), especially among children whose parents smoke. ... University of Arizona reports that those health risks persist ... individuals end up becoming smokers later in life. ...
... , SATURDAY, May 19 (HealthDay News) -- More than ... more than half of those victims are younger than age ... (May 20 to 26), the American Academy of Pediatrics is ... Postal Service to educate people about dog safety. They ...
Cached Medicine News:Health News:Biomarker predicts response to cancer treatment 2Health News:Obese adolescents have heart damage 2Health News:Test Baby Boomers for Hepatitis C, Says CDC 2Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 2Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 3Health News:Study says children exposed to tobacco smoke face long-term respiratory problems 2Health News:Study says children exposed to tobacco smoke face long-term respiratory problems 3Health News:Keeping Your Family Safe From Dog Bites 2
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
... Seven digital models cover the range from ... liquid fluently. Volume lock design prevents inadvertent ... the horizontal grip. Whole pipette is autoclavable ... ejector is all polypropylene. Suitable for one-handed ...
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: